Head and Neck Cancers

June 28, 2022

Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.

June 04, 2022

Avasopasem was associated with a significant reduction in severe oral mucositis in patients with locally nonmetastatic head and neck cancer undergoing chemoradiotherapy.

June 03, 2022

Kellie Zeichner, RN, BSN, OCN, discusses the production of biosimilars, their approval and naming processes, and why immunogenicity is important when discussing these agents.

April 24, 2022

The phase 3 RATIONALE 309 trial highlighted the combined efficacy of tislelizumab and chemotherapy in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.

April 01, 2022

A post-hoc efficacy analysis of KEYNOTE-048 found that CPS scores were linked to immunotherapy efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

April 07, 2021

The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

March 27, 2021

Tipifarnib showed promising clinical activity in patients with recurrent and/or metastatic, HRAS-mutant head and neck squamous cell carcinoma whose disease had progressed after prior therapy.

February 25, 2021

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.

August 13, 2020

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

June 15, 2020

On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.